# Jean-Paul Kress

> Jean-Paul Kress is a seed investor at Vor Biopharma (Boston) backing Medical and Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vor Biopharma](https://shizune.co/investors/profile/vor-biopharma)
- Location: Boston, United States
- Total investments: 1
- Last investment: Feb 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jean-paul-kress/
- Facebook: https://www.facebook.com/jeanpaul.kress

Jean-Paul Kress is a seed investor at Vor Biopharma in Boston focused on Medical and Biotechnology. Jean-Paul Kress is based out of Paris, Île-de-France and is the Chief Executive Officer and Chairman of the Board of Vor Biopharma and Independent Director of Sanofi. Jean-Paul previously worked at MorphoSys as a CEO. Jean-Paul Kress attended the Université de Paris.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LinKinVax | LinKinVax operates as a clinical-stage biotechnology company. LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). | $5M | Seed | Feb 10, 2022 |  |

1 of 1 investments shown.

## About Vor Biopharma

VC Fund · Cambridge, United States

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) Tcells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential. The company is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specifically targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies.

5 contacts available at Vor Biopharma.

| Name | Title | Profile |
| --- | --- | --- |
| Jean-Paul Kress | Chief Executive Officer | https://shizune.co/investors/profile/jean-paul-kress-3e46 |
| Amy Mendel | Chief Legal Officer | https://shizune.co/investors/profile/amy-mendel-0ec6 |
| Bill Lundberg | Independent Director | https://shizune.co/investors/profile/bill-lundberg |
| Christopher Slapak | Chief Medical Officer | https://shizune.co/investors/profile/christopher-slapak |
| John King | Chief Commercial Officer | https://shizune.co/investors/profile/john-king-956c |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Medical Angel Investors in France](https://shizune.co/investors/medical-angel-investors-france)
- [Biotechnology Angel Investors in France](https://shizune.co/investors/biotechnology-angel-investors-france)
- [Biotech Angel Investors in France](https://shizune.co/investors/biotech-angel-investors-france)

## FAQ

### What does Jean-Paul Kress invest in?

Jean-Paul Kress invests primarily in Medical and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jean-Paul Kress last invest?

The most recent investment recorded for Jean-Paul Kress closed in Feb 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co